InvestorsHub Logo
Followers 655
Posts 19476
Boards Moderated 6
Alias Born 07/03/2011

Re: Monksdream post# 92

Thursday, 03/07/2024 7:08:56 AM

Thursday, March 07, 2024 7:08:56 AM

Post# of 209
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
the study, which is the largest reported trial to date of CAR T therapy for solid tumors, evaluated CAR T cells engineered to target the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Ra2), a product invented at City of Hope and exclusively licensed by Mustang Bio Inc. (Nasdaq: MBIO), a Fortress Biotech Inc. (Nasdaq: FBIO) Company.
https://www.businesswire.com/news/home/20240307463963/en/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MBIO News